Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
semaglutide
Pharma
Novo Nordisk's semaglutide delivers in phase 3 MASH study
With a positive readout for MASH now in the bag, Novo Nordisk is gearing up to pursue yet another indication for its star GLP-1 medicine semaglutide.
Fraiser Kansteiner
Nov 1, 2024 10:38am
Novo asks FDA to prevent compounders from making GLP-1 knockoffs
Oct 23, 2024 2:29pm
Novo's oral semaglutide shows heart benefits
Oct 21, 2024 10:09am
Novo Nordisk rekindles heart failure hopes for semaglutide
Aug 30, 2024 11:48am
Study suggests possible suicidal ideation link to Novo's Ozempic
Aug 20, 2024 4:49pm
Novo won't file for IcoSema approval in US
Aug 13, 2024 1:40pm
